Literature DB >> 20066533

Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia.

Ellen Christina Obermann1, Caroline Arber, Martine Jotterand, Andre Tichelli, Petra Hirschmann, Alexandar Tzankov.   

Abstract

Mutations of the Fms-like tyrosine kinase 3 (FLT3) can be detected in a significant number of acute myeloid leukemias (AML). Seventy-five cases of acute myeloid leukemia were evaluated for FLT3-internal tandem duplications (ITD) by polymerase chain reaction. Paraffin-embedded formalin-fixed trephine biopsies of these cases were evaluated for expression of phosphorylated signal transducer and activator of transcription 1 (pSTAT1), pSTAT3, and pSTAT5. Specific expression of pSTAT5 was proven in leukemic blasts in situ by double staining with a blast-specific marker. Expression of pSTAT5 in > or =1% of blasts was highly predictive of FLT3-ITD. Neither expression of pSTAT1 nor pSTAT3 were associated with FLT3 mutations. Altogether we conclude that pSTAT5 expression can precisely be assessed by immunohistochemistry in routinely processed bone marrow trephines, STAT5 is highly likely the preferred second messenger of FLT3-mediated signaling in AML, and expression of pSTAT5 is predictive of FLT3-ITD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066533     DOI: 10.1007/s00277-009-0890-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  10 in total

1.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.

Authors:  Anindya Chatterjee; Joydeep Ghosh; Baskar Ramdas; Raghuveer Singh Mali; Holly Martin; Michihiro Kobayashi; Sasidhar Vemula; Victor H Canela; Emily R Waskow; Valeria Visconte; Ramon V Tiu; Catherine C Smith; Neil Shah; Kevin D Bunting; H Scott Boswell; Yan Liu; Rebecca J Chan; Reuben Kapur
Journal:  Cell Rep       Date:  2014-11-13       Impact factor: 9.423

3.  Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.

Authors:  Xiangmeng Wang; Po Yee Mak; Hong Mu; Wenjing Tao; Arvind Rao; Ravikumar Visweswaran; Vivian Ruvolo; Jonathan A Pachter; David T Weaver; Michael Andreeff; Bing Xu; Bing Z Carter
Journal:  Mol Cancer Ther       Date:  2020-05-13       Impact factor: 6.261

4.  Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.

Authors:  Timothy P Burkholder; Joshua R Clayton; Mark E Rempala; James R Henry; John M Knobeloch; David Mendel; Johnathan A McLean; Yan Hao; David A Barda; Eileen L Considine; Mark T Uhlik; Yuefeng Chen; Liandong Ma; Laura J Bloem; Jacqueline K Akunda; Denis J McCann; Manuel Sanchez-Felix; David K Clawson; Michael M Lahn; James J Starling
Journal:  Invest New Drugs       Date:  2011-03-01       Impact factor: 3.850

5.  Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.

Authors:  Gregory K Behbehani; Nikolay Samusik; Zach B Bjornson; Wendy J Fantl; Bruno C Medeiros; Garry P Nolan
Journal:  Cancer Discov       Date:  2015-06-19       Impact factor: 39.397

6.  Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Authors:  David B Rosen; Mark D Minden; Steven M Kornblau; Aileen Cohen; Urte Gayko; Santosh Putta; John Woronicz; Erik Evensen; Wendy J Fantl; Alessandra Cesano
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

7.  CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia.

Authors:  L Brault; A Rovó; S Decker; C Dierks; A Tzankov; J Schwaller
Journal:  Leukemia       Date:  2013-07-02       Impact factor: 11.528

8.  FLT3 mutations in canine acute lymphocytic leukemia.

Authors:  Steven E Suter; George W Small; Eric L Seiser; Rachael Thomas; Matthew Breen; Kristy L Richards
Journal:  BMC Cancer       Date:  2011-01-27       Impact factor: 4.430

9.  The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.

Authors:  Ugo Testa; Elvira Pelosi
Journal:  Leuk Res Treatment       Date:  2013-07-09

10.  High-fat diet intensifies MLL-AF9-induced acute myeloid leukemia through activation of the FLT3 signaling in mouse primitive hematopoietic cells.

Authors:  François Hermetet; Rony Mshaik; John Simonet; Patrick Callier; Laurent Delva; Ronan Quéré
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.